Table 1.

Characteristics of TP53 carriers and non-carriers from published studies reporting HER2 breast tumor status

Reference	Country of origin	Reported genetic testing information	Reported patient selection criteria	Total N	Purpose for this study
Melhem-Bertrandt et al., 2012	USA	Sequencing done at outside CLIA certified laboratories	Women with suspected LFS due to personal and/or family history and diagnosed with breast cancer between 2000 to 2011	119	Meta-analysis of available summary data to compare with results from our individual level study datasets (shown in Table 2)
Slavin et al., 2017	USA	Sequencing done for 26 known or proposed breast cancer susceptibility genes	BRCA1/2-negative women with familial breast cancer from four academic health centers in the USA	2134
Hauke et al., 2018	Germany	Sequencing done at each participating center using Illumina sequencing platforms	Patients meeting the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for germ line testing (familial cancer cases, patients with early onset breast cancer, bilateral breast cancer, or both breast and ovarian cancer)	2856
Packwood et al., 2019*	UK	Unreported	Women affected by early onset breast cancer	1296

^*Overlaps with Wilson et al., 2010, which reported on a subset of 9 TP53 carriers and 161 non-carriers from the same cohort.